Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-interferon Plus Ribavirin for HCC Prevention
NCT00375661Phase 4Completed
- Sponsor
- Kyoto University
- Start
- Sep 2006
- Primary completion
- Mar 2012
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2b, ribavirin in hepatocellular carcinoma (HCC), sponsored by Kyoto University. Started Sep 2006; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00375661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00375661.